Retatrutide vs Tirzepatide: Next-Generation Weight Loss Medications

The weight loss medication landscape is evolving rapidly. Tirzepatide (sold as Zepbound for weight loss and Mounjaro for diabetes) has already made waves as the most effective FDA-approved option available. But on the horizon is retatrutide—a next-generation “triple agonist” that’s showing even more impressive results in clinical trials.

If you’re considering one of these medications, you probably have questions: How do they compare? Which one is more effective? When will retatrutide be available? In this guide, we’ll break down the science, the data, and what each medication means for your weight loss journey.

What Are Retatrutide and Tirzepatide?

Both retatrutide and tirzepatide belong to a new generation of weight loss medications that work by mimicking natural hormones in your body. But they differ in how many hormones they target.

Tirzepatide: The Dual Agonist

Tirzepatide activates two hormone receptors:

• GLP-1 (glucagon-like peptide-1): Slows digestion, reduces appetite, and helps control blood sugar
• GIP (glucose-dependent insulinotropic polypeptide): Enhances insulin release and improves how your body processes fat

Tirzepatide is FDA-approved and available today as Zepbound (for weight loss and sleep apnea) and Mounjaro (for type 2 diabetes). Clinical trials showed an average weight loss of 21% over 72 weeks—making it the most effective weight loss drug currently on the market.

Retatrutide: The Triple Agonist

Retatrutide takes this approach one step further by activating three hormone receptors:

• GLP-1: Appetite suppression and blood sugar control
• GIP: Improved insulin function and fat metabolism
• Glucagon: Increases energy expenditure and fat burning

That third target—the glucagon receptor—is what sets retatrutide apart. By activating glucagon receptors, retatrutide may help your body burn more calories throughout the day, even at rest. In Phase 2 trials, retatrutide showed an average weight loss of 24.2% at 48 weeks, and recent Phase 3 data showed up to 28.7% weight loss at 68 weeks with the 12 mg dose.

Head-to-Head Comparison

Weight Loss Effectiveness: The Numbers

When it comes to the numbers, retatrutide appears to have the edge—at least based on early trial data:

• Tirzepatide: Average weight loss of 21% over 72 weeks (about 15 months)
• Retatrutide: Average weight loss of 24.2% at 48 weeks, with some participants losing up to 28.7% at 68 weeks

In real terms, if you weigh 250 pounds, that could mean losing around 52 pounds with tirzepatide compared to potentially 60–72 pounds with retatrutide. A network meta-analysis comparing the two found retatrutide resulted in an average absolute weight reduction of 16.34 kg (36 lbs) compared to 11.82 kg (26 lbs) for tirzepatide.

Important note: These are different trials with different populations, so it’s not a perfect apples-to-apples comparison. A direct head-to-head clinical trial comparing retatrutide to tirzepatide is currently being conducted by Eli Lilly, which will give us more definitive answers.

How They Work Differently

The key difference comes down to that third receptor—glucagon.

Both medications help you feel fuller longer and eat less by mimicking GLP-1 and GIP. But retatrutide’s activation of the glucagon receptor adds another dimension: it increases your metabolic rate and promotes fat breakdown. Think of glucagon as your body’s fat-burning accelerator—it tells your liver to break down stored fat for energy and helps increase overall calorie burn.

This triple action may be why retatrutide shows slightly higher weight loss numbers in trials. You’re not just eating less—your body is also burning more.

Side Effects Comparison

Both medications share similar side effect profiles, mainly affecting your digestive system:

• Nausea (the most common)
• Vomiting
• Diarrhea
• Constipation
• Stomach pain

According to meta-analysis data, adverse events occurred more frequently with retatrutide (risk ratio: 4.10) compared to tirzepatide (risk ratio: 2.78). This means retatrutide users were about 47% more likely to experience side effects compared to tirzepatide users in these studies.

However, it’s important to note that most side effects are temporary and tend to improve as your body adjusts to the medication. Both medications use gradual dose escalation to minimize these effects.

Dosing and Administration

Both medications are taken as once-weekly subcutaneous injections (under the skin), typically in the abdomen, thigh, or upper arm.

Tirzepatide Dosing

• Starting dose: 2.5 mg weekly
• Maintenance doses: 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly
• Dose increased every 4 weeks as tolerated

Retatrutide Dosing (in Clinical Trials)

• Studied doses: 1 mg up to 12 mg weekly
• Common trial doses: 4 mg, 8 mg, or 12 mg weekly
• Gradual titration over several weeks to minimize side effects

Important: Retatrutide dosing is not yet finalized since it’s still in clinical trials. The FDA will determine the approved dosing schedule if the medication is approved.

Availability and Cost

Tirzepatide Availability

Tirzepatide is FDA-approved and available now at pharmacies nationwide as:

• Zepbound: Approved for weight loss and sleep apnea
• Mounjaro: Approved for type 2 diabetes

Cost:

• List price: Around $1,060 per month without insurance
• With insurance: Coverage varies widely; many plans cover Mounjaro for diabetes but not Zepbound for weight loss
• Savings programs: Eli Lilly offers savings cards that can reduce costs significantly for eligible patients

Retatrutide Availability

Retatrutide is NOT yet FDA-approved and cannot be legally prescribed outside of clinical trials. Here’s what we know about its timeline:

• Current status: Phase 3 clinical trials underway
• Expected FDA submission: Late 2025 or early 2026
• Potential approval: Late 2026 to early 2027, though delays are common
• Market availability: Likely 2027, assuming trials remain positive

If you’re interested in accessing retatrutide now, you may be able to join a clinical trial. Check ClinicalTrials.gov or talk to your healthcare provider about trial eligibility.

Frequently Asked Questions

The Bottom Line

Retatrutide represents an exciting advance in obesity treatment, showing the potential for even greater weight loss than the already impressive tirzepatide. The addition of glucagon receptor activation appears to enhance fat burning and energy expenditure, leading to superior results in early trials.

However, tirzepatide is proven, approved, and available today—and it’s already delivering life-changing results for millions of people. With average weight loss around 21% and FDA approval for both weight loss and diabetes, it’s an excellent option that doesn’t require waiting or hoping.

The best medication is the one you can access and use consistently. For most people, that means starting with tirzepatide now rather than waiting years for retatrutide. If retatrutide proves superior once it’s approved, you’ll have options to switch. But in the meantime, you’ll already be well on your way to better health.

Talk to your healthcare provider about which approach makes the most sense for your weight loss goals, health status, and personal situation. The most important step is starting—whether that’s with tirzepatide today or retatrutide tomorrow.